News
ANAB
45.95
-0.56%
-0.26
AnaptysBio (ANAB) Gets a Buy from H.C. Wainwright
TipRanks · 4d ago
Weekly Report: what happened at ANAB last week (0928-1002)?
Weekly Report · 4d ago
AnaptysBio Is Maintained at Overweight by JP Morgan
Dow Jones · 09/30 18:13
AnaptysBio Price Target Cut to $60.00/Share From $70.00 by JP Morgan
Dow Jones · 09/30 18:13
JP Morgan Maintains Overweight on AnaptysBio, Lowers Price Target to $60
Benzinga · 09/30 18:04
AnaptysBio price target lowered to $60 from $70 at JPMorgan
TipRanks · 09/30 11:30
Weekly Report: what happened at ANAB last week (0921-0925)?
Weekly Report · 09/28 09:56
Is AnaptysBio (ANAB) Cheap On Its Royalty Story Despite Tax Driven Earnings?
Simply Wall St · 09/27 01:27
How Return To Profit Will Impact AnaptysBio (ANAB) Investors
Simply Wall St · 09/25 16:24
AnaptysBio Price Target Maintained With a $95.00/Share by HC Wainwright & Co.
Dow Jones · 09/24 14:40
HC Wainwright & Co. Reiterates Buy on AnaptysBio, Maintains $95 Price Target
Benzinga · 09/24 14:30
AnaptysBio price target lowered to $81 from $90 at Leerink
TipRanks · 09/23 13:35
AnaptysBio Price Target Cut to $81.00/Share From $90.00 by Leerink Partners
Dow Jones · 09/23 13:27
AnaptysBio Is Maintained at Outperform by Leerink Partners
Dow Jones · 09/23 13:27
Leerink Partners Maintains Outperform on AnaptysBio, Lowers Price Target to $81
Benzinga · 09/23 13:17
AnaptysBio (ANAB) Flags Positive AZUR 1 Data With Approval And Legal Timelines
Simply Wall St · 09/23 09:26
Analysts Offer Insights on Healthcare Companies: Quest Diagnostics (DGX), AnaptysBio (ANAB) and Vertex Pharmaceuticals (VRTX)
TipRanks · 09/23 09:10
AnaptysBio's Royalty Model Delivers Again, But the Real Verdict Remains With the Court
Barchart · 09/22 16:01
Analysts Conflicted on These Healthcare Names: Alcon (ALC), Xenon (XENE) and AnaptysBio (ANAB)
TipRanks · 09/22 12:50
Analysts’ Opinions Are Mixed on These Healthcare Stocks: AnaptysBio (ANAB), Alkermes (ALKS) and Iradimed (IRMD)
TipRanks · 09/22 10:50
More
Webull provides a variety of real-time ANAB stock news. You can receive the latest news about Anaptysbio Inc through multiple platforms. This information may help you make smarter investment decisions.
About ANAB
AnaptysBio, Inc. is a royalty management company. The Company manages the financial collaborations for Jemperli with GlaxoSmithKline (GSK) and imsidolimab with Vanda Pharmaceuticals Inc. (Vanda). The Company's financial collaboration with GSK is focused upon the development and commercialization of Anaptys-discovered Jemperli (dostarlimab), a PD-1 antagonist, approved for endometrial cancer and dMMR pan tumors, and is being studied in rectal cancer, colon cancer and head and neck squamous cell carcinoma. The Company's financial collaboration with Vanda is focused upon the development and commercialization of Anaptys-discovered imsidolimab, an IL-36R antagonist, which is being developed for generalized pustular psoriasis (GPP).